The landscape of litigation finance is shifting from a passive investment model to something far more aggressive, where the funders themselves often steer the course of legal battles. In recent years, we have seen a rise in “non-recourse” funding that, upon closer inspection, looks less like a safety net for plaintiffs and more like a high-stakes financial engine fueled by insurance premiums. To understand the intricacies of this evolution and the legal backlash it has triggered, we are joined by an expert in insurance litigation who has closely monitored the unfolding federal case between New York Marine & General Insurance Company and Case Cash Funding. This discussion explores the mechanics of claim control, the securitization of legal receivables, and the ethical implications of a system where claimants sometimes receive only a fraction of their own settlements.
When a funder blocks a settlement that mediators and attorneys have already deemed fair, how does this shift the fundamental nature of the legal process from resolution to a financial pursuit?
This is where the friction between legal ethics and high-yield investment becomes incredibly visible and, frankly, quite jarring for everyone in the room. In a typical mediation, you have all parties, including neutral mediators and the claimant’s own counsel, reaching a consensus—in one documented instance, they agreed $750,000 was a fair and reasonable settlement for the injuries sustained. However, when a funder who only advanced $76,500 suddenly asserts a lien of $1,419,364.44, the entire machinery of justice grinds to a halt. It transforms a legal claim into a commodity where the objective isn’t to make the plaintiff whole, but to hit a specific return target for investors. This creates a situation where a passive investor is no longer passive; they are effectively forcing the case into further litigation because they need a much larger payout to satisfy their internal financial metrics.
The term “non-recourse” is often used to describe these advances, but what happens when this label is viewed as mere “window dressing” for a much more controlling relationship?
The label “non-recourse” is supposed to mean that the claimant only pays if they win, but the reality described in recent litigation suggests a much more hands-on, almost suffocating level of control. We are seeing allegations that funders are not just providing capital but are actually running the entire life of a claim, from paying clinics for referrals to steering claimants toward specific lawyers who are kept loyal through interest-free “personal loans.” There are even claims that funding is tied to claimants undergoing specific surgeries, which creates a disturbing incentive structure where medical decisions are influenced by litigation strategy. This isn’t just lending; it is a holistic management of the case that ensures the funder is the primary beneficiary. When you see a funder blocking settlements that the attorney and the client want to take, the “non-recourse” facade falls away to reveal a lender who is essentially the shadow plaintiff.
How does the securitization of these legal claims, such as the PEAR 2022-1 instrument, change the way insurers are viewed by the litigation finance industry?
Securitization takes individual human tragedies and bundles them into a massive, cold financial product that is sold to institutional investors. In the case of the PEAR 2022-1 instrument, we are looking at an outstanding receivable balance of $84,619,110.66 spread across 16,807 individual advances. What is truly revealing is how these bundles are marketed; they aren’t just collections of random lawsuits, but are instead sorted by the NAIC rating of the insurance carriers whose policies are expected to pay the claims. This effectively names the insurers as the “payment source” in the deal documents, making them the actual targets of the business model. It suggests that the funder isn’t betting on the merits of the individual cases, but rather on their ability to extract a specific volume of cash from highly-rated insurance companies.
When looking at the actual payouts, such as a claimant receiving only 13.3% of a multimillion-dollar settlement, what does that say about the intended purpose of this funding?
It paints a heartbreaking picture of a system that has arguably lost its way. When a settlement of $3,750,000 results in a claimant walking away with only 13.3% while the funder takes 47.5%, the funder is no longer “helping” the injured party—they are the primary stakeholder. We see even more egregious examples, like an Afghan refugee who spoke no English and believed he was taking a $25,000 loan at a modest 3.5% interest rate, only to have his lawyers cut a check to the funder for $67,545.78. That represents a 170% interest payment, a figure that led to reports being filed with the District Attorney and the Governor’s office. These numbers suggest that the funding is designed to exploit the gap between a claimant’s immediate need for cash and the ultimate value of their legal rights.
What are the primary legal strategies being employed to challenge these funding models, and why are we seeing claims like RICO and the Lanham Act being utilized?
Insurers are getting creative because the traditional defenses aren’t stopping the tide of inflated claims, so they are turning to powerful federal statutes like the Lanham Act and RICO. By using the Lanham Act, an insurer can argue that the funder’s deceptive advertising—claiming to offer “loans” that are actually predatory investments—directly harms the insurer’s business interests. The argument rests on the Supreme Court’s Lexmark decision, suggesting insurers fall within the “zone of interests” because the entire predatory ecosystem is built to drain their reserves. They are also layering in common-law barratry and public-nuisance counts to show that this behavior isn’t just a private contract issue, but a systemic perversion of the legal system. If these theories hold up in court, it gives carriers a massive new tool to sue funders directly rather than just fighting individual claims one by one.
What is your forecast for the future of litigation funding regulation and its impact on the insurance industry?
I expect we will see a significant shift toward mandatory transparency where funders will be forced to disclose their financial interests early in the litigation process. As more cases like the one involving New York Marine reach the federal courts, judges will likely have to rule on whether these “non-recourse” advances are actually unlawful loans that violate state usury laws. If the courts agree that insurers are the intended targets of these securitized bundles, we could see a wave of “counter-litigation” where insurance companies aggressively pursue funders for deceptive practices. This will likely lead to a cooling effect on the more aggressive funding models, as the risk of being sued for RICO violations or barratry will make it harder to sell these legal receivables to conservative investors. Ultimately, the industry will have to move back toward a model that prioritizes the claimant’s recovery over the funder’s return target.
